TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Aditxt ( (ADTX) ) is now available.
On July 22, 2025, Aditxt‘s CEO, Amro Albanna, presented at Wall Street Reporter’s Next Super Stock event about Adimune, Inc., a subsidiary focused on immunotherapy. The presentation highlighted Adimune’s ongoing and planned product development, funding needs, and market targets, emphasizing the potential impact on the company’s operations and market positioning. However, the company also acknowledged various risks and uncertainties that could affect future outcomes.
More about Aditxt
Aditxt, Inc. operates in the biotechnology industry, focusing on developing immune monitoring technologies and therapeutics. The company is involved in the advancement of its subsidiary, Adimune, Inc., which is working on product and business development in the field of immunotherapy.
Average Trading Volume: 787,846
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.99M
For detailed information about ADTX stock, go to TipRanks’ Stock Analysis page.